Enzolytics Inc. (OTCPK:ENZC) executed a non-binding letter of intent to acquire BioClonetics Immunotherapeutics, Inc. on September 15, 2020. Enzolytics Inc. entered into an agreement to acquire BioClonetics Immunotherapeutics, Inc. on October 19, 2020. The BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics' flagship compound ITV-1 which is a suspension of Inactivated Pepsin Fragment. The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as Chief Executive Officer of the merged entity and Harry Zhabilov and Joseph Cotropia, Managing Director, being appointed as Co-Cso. Gaurav Chandra, Managing Director, will serve as Chief Operating Officer of the merged entity. As of October 1, 2020, Harry Zhabilov, Chief Executive Officer of Enzolytics will also be joining the Board of Directors of BioClonetics. Enzolytics Inc. (OTCPK:ENZC) completed the acquisition of BioClonetics Immunotherapeutics, Inc. on December 1, 2020.